Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
P01 – Additional radiochemotherapy versus neoadjuvant chemotherapy alone in locally advanced pancreatic adenocarcinoma
2013-001028-21Phase 2Terminated
- Sponsor
- Austrian Breast and Colorectal Cancer Study Group
- Start
- Apr 2013
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of gemcitabine and oxaliplatin in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Austrian Breast and Colorectal Cancer Study Group. Primary endpoint: Histological R0 resection rate. Started Apr 2013; status: terminated.
02
Drugs
gemcitabineoxaliplatin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2013-001028-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001028-21.